Scott Adams, the creator of popular comic strip “Dilbert,” has revealed that his odds of surviving cancer are slim to none.

Dilbert’ creator says his prostate cancer has spread and ‘it’s all bad news’ - Scott Adams previously asked President Donald ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

The creator of the iconic Dilbert comic strip, Scott Adams, has shared a distressing update regarding his ongoing battle with ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

SAN FRANCISCO -- Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy (MDT) in addition to systemic treatment, a meta-analysis of ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...